SPARC secures exclusive license for Alopecia Areata Treatment

Sun Pharma Advanced Research Company Ltd. (SPARC) has announced a significant milestone in the field of alopecia areata treatment. In collaboration with Johns Hopkins University (JHU) and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB), SPARC has obtained an exclusive worldwide license for SCD-153, along with all associated patents and patent applications.

Following a comprehensive evaluation under a Material Transfer Agreement (MTA), SPARC progressed to an Option to License Agreement with the esteemed licensors. The Indian regulatory authority, the Drug Controller General of India (DCGI), has granted approval for SPARC's Investigational New Drug (IND) application.

The licensing agreement outlines provisions for upfront payments, milestone-based payments linked to regulatory and sales achievements, and a structured royalty framework based on sales performance. This collaboration underscores SPARC's commitment to pioneering advancements in dermatological solutions.

CEO of SPARC, Anil Raghavan, expressed enthusiasm about this venture, emphasizing its potential to offer a crucial treatment option for alopecia areata. This strategic partnership exemplifies SPARC's dedication to driving innovation through dynamic collaborations with academic institutions. With the successful development of topical SCD-153, SPARC aims to significantly impact the treatment landscape for this dermatological condition.